Mitchell Lawrence Jones - 21 Nov 2023 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PALI	Restricted Stock Units	Award	$0	+28,000		$0.000000	28,000	21 Nov 2023	Common Stock	28,000		Direct	F1, F2, F3, F4
transaction	PALI	Common Stock Options	Award	$0	+33,160		$0.000000	33,160	21 Nov 2023	Common Stock	33,160	$0.5900	Direct	F1, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting.
F2	Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
F3	The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024.
F4	N/A.
F5	Each option represents the right to purchase one share of common stock at the exercise price.
F6	The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date.